QUE Oncology
Melbourne
About QUE Oncology
QUE Oncology, Inc. (QUE) was formed through a collaboration between Emory University, in Atlanta, Georgia, and The University of Queensland (UQ) research commercialization company, UniQuest, in Brisbane, Australia. QUE licenses intellectual property originating from research discoveries at both UQ and Emory’s Institute for Drug Development (EIDD). The leading drug candidate is Q-122, a compound with anti-inflammatory properties that is in Phase 1b clinical development for the treatment of hot flashes in women with breast cancer who are receiving anti-estrogen therapy. Additional cancer research projects that have been identified to supply the QUE Oncology pipeline are designed to address prostate cancer, breast cancer, melanoma, and cancer pain.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $16.5M
- Funding stage: Early Stage Venture
- Last round: Series A (Jun 2017)
- Website: queoncology.com
Industries & Categories
Biopharma, Biotechnology, Health Care, Oncology, Therapeutics
Canonical: https://fsome.com/organization/que-oncology-194738 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.